• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Limitations of Radiographic Response Assessments of Systemic Therapy for Advanced Hepatocellular Carcinoma.

作者信息

Lau-Min Kelsey S, Franses Joseph W

机构信息

Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA.

Department of Medicine, Section of Hematology-Oncology, University of Chicago, Chicago, IL.

出版信息

JCO Precis Oncol. 2025 Aug;9:e2500551. doi: 10.1200/PO-25-00551. Epub 2025 Aug 18.

DOI:10.1200/PO-25-00551
PMID:40825168
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12363656/
Abstract
摘要

相似文献

1
Limitations of Radiographic Response Assessments of Systemic Therapy for Advanced Hepatocellular Carcinoma.晚期肝细胞癌全身治疗的影像学反应评估的局限性
JCO Precis Oncol. 2025 Aug;9:e2500551. doi: 10.1200/PO-25-00551. Epub 2025 Aug 18.
2
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma.ADP - A2AFP TCR T细胞疗法用于晚期肝细胞癌或胃肝样腺癌患者的I期试验。
J Hepatol. 2025 Aug 12. doi: 10.1016/j.jhep.2025.07.033.
3
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.钇-90微球放射性栓塞治疗不可切除的肝细胞癌
Cochrane Database Syst Rev. 2016 Feb 16;2:CD011313. doi: 10.1002/14651858.CD011313.pub2.
4
Prognoses of Patients Treated With Surgical Therapy Versus Continuation of Local-Plus-Systemic Therapy Following Successful Down-Staging of Intermediate-Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study.中晚期肝癌降期治疗后手术治疗与局部联合全身治疗延续治疗患者预后的多中心真实世界研究。
Oncologist. 2024 Apr 4;29(4):e487-e497. doi: 10.1093/oncolo/oyad277.
5
A Contrast-Enhanced Ultrasound Cine-Based Deep Learning Model for Predicting the Response of Advanced Hepatocellular Carcinoma to Hepatic Arterial Infusion Chemotherapy Combined With Systemic Therapies.一种基于超声造影动态图像的深度学习模型，用于预测晚期肝细胞癌对肝动脉灌注化疗联合全身治疗的反应。
Cancer Sci. 2025 Jul;116(7):1930-1940. doi: 10.1111/cas.70089. Epub 2025 Apr 29.
6
Immune Checkpoint Inhibition for Hepatocellular Carcinoma, Cholangiocarcinoma, and Combined Hepatocellular-Cholangiocarcinoma.免疫检查点抑制剂治疗肝细胞癌、胆管癌及肝内胆管癌合并肝细胞癌
World J Oncol. 2025 Jun;16(3):243-253. doi: 10.14740/wjon2571. Epub 2025 May 13.
7
External beam radiotherapy for unresectable hepatocellular carcinoma.不可切除肝细胞癌的外照射放疗
Cochrane Database Syst Rev. 2017 Mar 7;3(3):CD011314. doi: 10.1002/14651858.CD011314.pub2.
8
Optimal sequencing of locoregional and systemic therapies for intermediate and advanced hepatocellular carcinoma: a network meta-analysis.中晚期肝细胞癌局部区域和全身治疗的最佳序贯：一项网状Meta分析。
J Cancer Res Clin Oncol. 2025 Jun 25;151(6):196. doi: 10.1007/s00432-025-06233-7.
9
Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis.早期和极早期肝细胞癌的消融和非手术治疗：系统评价和网络荟萃分析。
Health Technol Assess. 2023 Dec;27(29):1-172. doi: 10.3310/GK5221.
10
Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.帕博利珠单抗单药治疗与化疗用于治疗含铂化疗期间或之后疾病进展的晚期尿路上皮癌。一项Cochrane快速综述。
Cochrane Database Syst Rev. 2018 Jul 23;7(7):CD012838. doi: 10.1002/14651858.CD012838.pub2.

本文引用的文献

1
Intrapatient Variation in Response to Systemic Therapy in Advanced Hepatocellular Carcinoma.晚期肝细胞癌患者对全身治疗反应的个体内差异
JCO Precis Oncol. 2025 Jul;9:e2500015. doi: 10.1200/PO-25-00015. Epub 2025 Jul 16.
2
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.纳武利尤单抗联合伊匹木单抗对比乐伐替尼或索拉非尼作为不可切除肝细胞癌一线治疗的疗效（CheckMate 9DW）：一项开放标签、随机、3期试验
Lancet. 2025 May 24;405(10492):1851-1864. doi: 10.1016/S0140-6736(25)00403-9. Epub 2025 May 8.
3
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.特瑞利木单抗联合度伐利尤单抗治疗不可切除肝细胞癌。
NEJM Evid. 2022 Aug;1(8):EVIDoa2100070. doi: 10.1056/EVIDoa2100070. Epub 2022 Jun 6.
4
Tumor heterogeneity: preclinical models, emerging technologies, and future applications.肿瘤异质性：临床前模型、新兴技术及未来应用
Front Oncol. 2023 Apr 28;13:1164535. doi: 10.3389/fonc.2023.1164535. eCollection 2023.
5
Spontaneous Immune-Mediated Regression of Hepatocellular Carcinoma With High Tumor Mutational Burden.肿瘤突变负荷高的肝细胞癌的自发免疫介导消退
JCO Precis Oncol. 2021 Jun 17;5. doi: 10.1200/PO.21.00092. eCollection 2021.
6
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.肝内和肝外胆管癌的危险因素：系统评价和荟萃分析。
J Hepatol. 2020 Jan;72(1):95-103. doi: 10.1016/j.jhep.2019.09.007. Epub 2019 Sep 16.
7
Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival.晚期 HCC 的随机试验和终点：PFS 作为生存替代指标的作用。
J Hepatol. 2019 Jun;70(6):1262-1277. doi: 10.1016/j.jhep.2019.01.028. Epub 2019 Mar 31.
8
Discrepancies of assessments in a RECIST 1.1 phase II clinical trial - association between adjudication rate and variability in images and tumors selection.在 RECIST 1.1 二期临床试验中评估的差异 - 裁决率与图像和肿瘤选择的变异性之间的关系。
Cancer Imaging. 2018 Dec 11;18(1):50. doi: 10.1186/s40644-018-0186-0.
9
Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib.晚期肝细胞癌患者在接受多激酶抑制剂索拉非尼治疗时的早期MRI反应监测
BMC Cancer. 2009 Jun 28;9:208. doi: 10.1186/1471-2407-9-208.
10
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).实体瘤新的疗效评价标准：修订的RECIST指南（第1.1版）
Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.